https://www.selleckchem.com/products/at13387.html
gression and dramatic progression. 2020 Journal of Thoracic Disease. All rights reserved.Background Transcatheter aortic valve implantation (TAVI) has become the gold standard for high-risk severe aortic stenosis. However, the experience of treating aortic regurgitation (AR) with this technology is still limited. Previously, we have demonstrated excellent 1-year outcomes of transapical TAVI with J-ValveTM (JieCheng Medical Technology Co., Ltd., Suzhou, China) in treating predominant AR, while the mid-term outcomes up to 4 years have nev
Like
Comment
Share
